Bleeding complications in anticoagulant treatment: An analysis of risk factors;Complicaciones hemorrágicas del tratamiento anticoagulante: Análisis de factores predictores de riesgo

Sangre

Volumn 44, Issue 3, 1999, Pages 216-221

  De Castroviejo, Eduardo Vázquez Ruiz ^a   Del Monte Trujillo Perez M ^a   Cabezas, Cristóbal Lozano ^a   Molina, Carmen Avellaneda ^a   Herrera, Manuel Guzmán ^a   Galiano, Eufrasio Martinez ^a   Sanfeliú, Hipólito Pousibet ^a   Castellani, Ada Tarabini ^a   Vilardebó, Carlos Pagola ^a   Muñoz, Antonio Alcalá ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CHEMICALLY INDUCED DISORDER; COMORBIDITY; DIABETES MELLITUS; DRUG INTERACTION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HOSPITALIZATION; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; SPAIN; STATISTICS; VALVULAR HEART DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD TRANSFUSION; CEREBRAL HEMORRHAGE; COMORBIDITY; DIABETES MELLITUS; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HEART DISEASES; HEART VALVE DISEASES; HEMORRHAGE; HOSPITALIZATION; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 0033144621     PISSN: 00364355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Petersen P, Boysen G, Godtfredesen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-179.
2. The SPAF Investigators. The Stroke Prevention in Atrial Fibrillation Study Group Investigators: Final results. Circulation 1991; 84: 527-539.
3. Cunnolly SJ, Laucpacis A, Gent M, Toberts RS, Cairns JA, Joyner C, for the CAFA study coninvestigators. Canadian atrial fibrilation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-355.
4. Ezekowitz MD, Brdigers SL, James KE, Carliner NH, Colling CL, Gornik CC et al. Forthe Veterans Affair Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Eng J Med 1992; 327: 1406-1412.
5. The EAFT Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack of minor stroke. Lancet 1993; 342: 1255-1262.
6. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for preventior of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994, 343: 687-691.
7. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical-trial. Lancet 1996, 348: 633-638.
8. Fihn SD, Mcdonell M, Martin D, Henikoff J, Vrme D, Kent D et al. For the Warfarin Optimized Outpatient Follow-up Study Group. Risk factors for complications of chronic anticoagulation. A Multicenter Study. Ann Intern Med 1993; 118: 511-520.
9. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
10. Bussey HI, Rospond RM, Quandt CM, Clark GM. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy 1989; 9: 214-129.
11. Petty GW, Lennihan L, Mohr JP, Hauser WA, Weitz J, Owen J et al. Complications of long term anticoagulation. Ann Neurol 1988; 23: 570-574.
12. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 1991; 229: 35-355.
13. Petitti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thrombocmbolism and hemorrhage. Am J Med 1986; 81: 225-259.
14. Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Age-related risks of long-term ora anticoagulant therapy. Arch Intern Med 1988; 148: 1733 - 1736.
15. Landefeld CS, Andersen PA, Goodnough LT, Moir TW, Horn DL, Rosenhlatt MW et al. The bleeding severity index: validation and comparison to other methods for classifying Bleeding complications of medical therapy. J Clin Epidemiol 1989; 42: 71-718.
16. Landefeld CS, Cook EF, Flatley BS, Weisberg RN, Goldman L. Identification and pre iminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82: 703-713.
17. Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy. N Eng J Med 1975; 292: 1046-1050.
18. Pauker SG, Eckman MH, Levine HJ. A decision analytic view of anticoagulant prophylaxis for thromboembolism in heart disease. Chest 1986; 89: 99S-106S.
19. Van der Meer FJM, Rosendaal FR, Vandcnbrouckc JP, Brië TE. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993; 153: 1557-1562.
20. Acar J, lun B, Boiseel JP, Samama MM, Michel PL, Teppe J et al. The AREVA Group. AREVA: Multicenter randomized comparison of low-dose versus standar-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996; 94: 2107-2112.
21. Levine MR, Raskob G, Hirsh J. Hemorragic complications of longterm anticoagulant therapy. Chest 1986; 89: 16S-25S.
22. Sach JJ, Henderson RR: Use de bishydroxycoumarin(dicumarol) in the presence of impaired renal function. JAMA 1952; 148: 839-841.
23. Kliesch WF, Davis WD. Dangers of prolonged anticoagulant therapy in hepatic disease. JAMA 1960; 172: 223-226.
24. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
25. Ansell J, Patel N, Ostrovsky D, Nozzolillo E, Peterson AM, Fish L. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995; 155: 2185-2189.
26. Leaning KE, Ansell JE. Advances in the monitoring of oral anticoagulation: Point-of-care testing, patient self-monitoring, and patient selfmanagement. J Thromb Trombolysis 1996; 3: 377-383.
27. Mair H, Welz A, Kreuzer E, Reichart B. INR-Home monitoring is a improvement in long term anticoagulation and quality of life after heart valve replacement. Circulation 1996; 94: (Suppl. 8). I-651.